Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism

C. Rantzau, M. Christopher, and F. P. Alford

Department of Endocrinology and Diabetes and Department of Medicine, St. Vincent’s Hospital, Fitzroy, and University of Melbourne, Parkville, Victoria, Australia

Submitted 9 May 2007; accepted in final form 5 November 2007

Rantzau C, Christopher M, Alford FP. Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism. J Appl Physiol 104: 363–370, 2008. First published November 21, 2007; doi:10.1152/japplphysiol.00500.2007.—The increased energy required for acute moderate exercise by skeletal muscle (SkM) is derived equally from enhanced fatty acid (FA) oxidation and glucose oxidation. Availability of FA also influences contracting SkM metabolic responses. Whole body glucose turnover and SkM glucose metabolic responses were determined in paired dog studies during 1) a 30-min moderate exercise (maximal oxygen consumption of ~60%) test vs. a 60-min low-dose 5-aminimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) infusion, 2) a 150-min AICAR infusion vs. modest elevation of FA induced by a 150-min combined intralipid-heparin (IL/hep) infusion, and 3) an acute exercise test performed with vs. without IL/hep. The exercise responses differed from those observed with AICAR: plasma FA and glycerol rose sharply with exercise, whereas FA fell and glycerol was unchanged with AICAR; glucose turnover and glycolytic flux doubled with exercise but rose only by 50% with AICAR; SkM glucose-6-phosphate rose and glycogen content decreased with exercise, whereas no changes occurred with AICAR. The metabolic responses to AICAR vs. IL/hep differed: glycolytic flux was stimulated by AICAR but suppressed by IL/hep, and no changes in glucose turnover occurred with IL/hep. Glucose turnover responses to exercise were similar in the IL/hep and non-IL/hep, but SkM lactate and glycogen concentrations rose with IL/hep vs. that shown with exercise alone. In conclusion, the metabolic responses to acute exercise are not mimicked by a single dose of AICAR or altered by short-term enhancement of fatty acid supply.

hepatic glucose production; glucose disposal; metabolic clearance rate of glucose; glycolytic flux; muscle biopsy; dog

WITH SHORT-TERM moderate exercise [maximal oxygen consumption (VO2max) of ~55–65%], total energy expenditure in skeletal muscle (SkM; i.e., ATP production) increases ~10- to 12-fold from the resting state. This increased energy debt is outstripped by enhanced ATP production from plasma, as supplied from normally met approximately equally by enhanced fatty acid (FA) oxidation (FAox) (derived from plasma, as supplied from adipocyte depot and intramuscular fat lipolysis) and glucose uptake and Gox (3, 21, 26, 28) and promotion of FAox (28, 30, 46). The latter is mediated by deactivation of acetyl-CoA carboxylase (ACCB) by AMPK-activated site-specific phosphorylation of Ser270 on ACCB (ACCB-pSer270) (7, 28, 32, 46). This leads to reduced intracellular malonyl CoA and hence activation of SkM carnitine palmitoyltransferase-1, which facilitates long-chain FA entry into mitochondria for oxidation and ATP generation (28). Activation of endogenous AMPK involves both covalent [via phosphorylation of Thr172 by AMPK (24, 51, 53)] and allosteric [via rising AMP-to-ATP ratio (24, 51)] mechanisms, which lead to an increase of measured endogenous SkM ACCB-pSer270 (7, 28, 32, 46), as previously discussed (5, 6, 8, 9). Of the two AMPK catalytic subunits (α1 and α2), only the α2-subunit is activated by moderately intense exercise (19, 48, 52), whereas the α1-subunit can be activated by extreme exercise (7).

Endogenous AMPK is also activated pharmacologically and nonspecifically by 5-aminimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), which is phosphorylated in vivo to the AMP analog AICAR monophosphate (ZMP) (12). AICAR activates AMPK-α2 by specific phosphorylation of Thr172, which then promotes a similar metabolic cascade in SkM as outlined above for exercise (3, 28, 30, 45, 46). Because of evidence that a similar activation of the AMPK metabolic cascade occurs in SkM by AICAR, the suggestion has arisen that in vivo administration of AICAR may simulate the metabolic benefits gained from exercise, especially in diabetic subjects (51). However, raised levels of ZMP can also allosterically directly activate other enzymes, such as glycogen phosphorylase (independent of AMPK activation) in cardiac muscle (4, 27) and liver (42).

Despite the apparent similarities between exercise and AICAR’s metabolic actions in SkM, important differences have emerged between exercise and AICAR-induced changes in SkM Gox and FAox. In particular, with increasing intensities of exercise, Gox continues to progressively rise, whereas FAox reaches a peak at VO2max of ~70% and thereafter declines (39, 49), despite the steady rise in AMPK-α activity through all intensities of exercise (14). Furthermore, uncertainties exist as to whether exercise and AICAR-stimulated AMPK activation have the same metabolic responses in SkM. For example, initial studies failed to demonstrate increased AICAR-induced

Address for reprint requests and other correspondence: F. P. Alford, Dept. of Endocrinology and Diabetes, 4th Floor Daly Wing, St Vincent’s Health, 35 Victoria St., Fitzroy Victoria 3065, Australia (e-mail: frank.alford@svhm.org.au).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
AICAR infusion, and how an excess supply of FA during exercise during an intralipid-heparin (IL/hep) infusion are also unchanged, whereas ZMP (0.00 to 0.24 min^{-1}) and AICAR (0.00 to 0.12 ± 0.04 μmol/g wet wt) concentrations are raised (9).

Experiment 4: IL/hep infusion (with and without exercise) studies.

The standard [3-3H]glucose clamp was combined with heparin (30-s priming bolus of 6 IU/kg followed by a continuous infusion of 12 IU·kg^{-1}·h^{-1}) and 20% IL (Fresenius Medical Care, Sydney, NSW, Australia) (5 min priming bolus of 6.6 ml/kg followed by a continuous infusion of 1.35 ml·kg^{-1}·h^{-1}) for the duration of each study. The aim of this protocol was to increase plasma FFA by 1.5- to 2.0-fold. On one day (random order), the 30-min exercise test was performed from minute 150 to minute 180; on the other day, the FA infusion was continued without exercise to 180 min.

**Metabolite and Glucose Turnover Measurements**

Plasma levels of glucose, total insulin, FFA, glycerol, glucagon, and lactate and specific activities of plasma [3-3H]glucose and [3H]H_2O were measured as previously described (8–11). The mean coefficients of variation obtained for plasma glucose and total insulin levels and [3-3H]glucose-specific activities during the steady-state periods of experiments 2, 3, and 4 were similar to those obtained in our earlier studies (8–11). The average rates of total glucose appearance, R_a, and MCR_g were calculated from minute 120 to minute 150 preexercise and pre-AICAR infusion period and during the 30-min exercise period (minute 150 to 180, with or without IL/hep), employing plasma [3-3H]glucose-specific activities and using either steady-state equations or, when not at steady state, Steele's nonsteady-state equations (47). A glucose pool fraction of 0.65 and a glucose volume of distribution of 200 ml/kg were employed for these calculations (8–11). The measurement of the rate of in vivo glycolysis (GF_{exog}) from
extracellularly derived glucose was estimated during steady state from the linear generation of plasma \(^{3}\text{H}_{2}\text{O}\) from the \([3-\text{H}]\text{glucose}\) (15) using the formula previously detailed from our laboratory (8–11).

During exercise, \(GF_{\text{extr}}\) was calculated as \(R_{b}\) (exercise) – \(GF_{\text{extr}}\) (basal), as previously described (8, 10, 39, 49).

**SKM Biopsy Studies**

Before and at the completion of both exercise studies (with and without IL/hep) and the AICAR and IL/hep infusions, SKM biopsy samples (4–5 passes) were taken from the thigh (vastus lateralis). Rapid induction of anesthesia was accomplished with a 4.2-mg/kg iv bolus followed by a 1.8-mg/kg iv titration of Diprivan (propofol, 2,6-disopropylphenol; AstraZeneca, North Ryde, Australia), as previously described (8–10). Each SKM biopsy sample was immediately frozen in liquid nitrogen (within 5 s of biopsy) and stored at \(-80^\circ\text{C}\) until assayed (8, 9). For each dog, the opposite back leg was used for the subsequent muscle biopsy procedure. SKM concentrations of intracellular glucose, glucose-6-phosphate (G6P; in mmol/kg dry wt), glycogen (mmol glucose residues/kg dry wt), and lactate were determined (8, 9) with a fluorometric enzyme-coupled assay, as modified from the method of Schalin-Jantti et al. (41). SKM intracellular glucose and lactate concentrations are expressed as millimoles per liter of intracellular water, assuming an extracellular water content in the biopsies of 0.3 l/kg dry wt and an intracellular water content in the biopsies of 2.8 l/kg dry wt, the justifications of which were discussed previously (8–10, 43, 44). AMPK-\(\alpha_{1}\) and AMPK-\(\alpha_{2}\) activities and concentrations of ACC\(\beta\)-pSer\(^{221}\) (human sequence), ATP, AMP, ZMP, and AICAR were measured in SkM, as previously described (7–9).

**Statistical Analysis**

Values are presented as means ± SE. Within-group and between-group responses for paired data were compared with Student’s \(t\)-test. Computations were carried out with Minitab II program (release 13; Minitab).

## RESULTS

**Exercise vs. AICAR Infusion**

With 30 min of moderate exercise, plasma glucose, insulin [4.1 ± 1.0 (before) vs. 3.0 ± 0.5 mU/l (after)], and glucagon [75 ± 17 (before) vs. 93 ± 21 ng/l (after); \(P = 0.05\) and \(NS\) for exercise] were increased (change of 35%), whereas insulin and glucagon were unchanged (insulin = 4.7 ± 0.5 (before) vs. 6.1 ± 0.8 mU/l (after); \(P = NS\); glucagon = 53 ± 11 (before) vs. 68 ± 11 ng/l (after); \(P = NS\)); plasma FFA decreased significantly (\(P < 0.01\)), with no change in glycerol, and lactate rose sharply (\(P < 0.01\)) (Fig. 1). Thus the incremental responses of FFA and glycerol to exercise and AICAR were significantly different and in the opposite directions (Fig. 1). There was a greater than twofold increase (\(P < 0.02–0.01\)) in HGP, GF\(_{\text{extr}}\), MCR\(_{g}\), and GF\(_{\text{extr}}\) after the 30-min moderate exercise test (Fig. 2). In contrast, although these parameters also increased after the 60-min AICAR infusion (\(P < 0.02\), the responses were considerably less (−30–40%) and significantly (\(P < 0.01\)) smaller for the AICAR than for the exercise responses (Fig. 2). The metabolic responses to AICAR at 150 min were similar to those obtained at 60 min, with only a minor attenuation of MCR\(_{g}\) by 150 min. SKM substrate concentrations of intracellular glucose and lactate did not change with exercise alone, whereas G6P significantly increased (change of 1.0 ± 0.3 mmol/l; \(P = 0.05\)) and glycerol decreased (change of −35 ± 36 mmol/kg dry wt; \(P = 0.06\)). In contrast, during AICAR infusion, a decrease in intracellular SKM glucose (change of −0.20 ± 0.09 mmol/l; \(P = 0.06\)) was noted, but no significant changes occurred in G6P, lactate, or glycogen. However, the absolute decrease of the glycogen concentration was significantly different for exercise compared with that for AICAR (change of −35 ± 36 vs. 9 ± 36 mmol/kg dry wt; \(P = 0.06\)). There were no changes in AMPK-\(\alpha_{1}\) and AMPK-\(\alpha_{2}\) activities with exercise or AICAR infusion (data not shown), but ACC\(\beta\)-pSer\(^{221}\) was elevated by 35% [from basal level of 1.05 ± 0.02 to 1.38 ± 0.15 (\(P = 0.05\)) with exercise and to 1.32 ± 0.15 (arbitrary units) (\(P = 0.06\)) with AICAR].

![Fig. 1. Paired comparisons of absolute plasma substrate responses and incremental changes (A) after either 30-min moderate exercise [exer; −60% maximal oxygen consumption (\(V_{\text{O}_{2\text{max}}}\)); open bars] or 60-min low-dose 5-aminimidazole-4-carboxamide-1-\(\beta\)-D-ribofuranoside (AICAR) infusion (hatched bars) in 6 dogs. A: plasma (P) glucose. B: plasma free fatty acid (FFA). C: lactate. D: glycerol. \(*P = 0.05; **P < 0.01\) vs. the within-group basal state; ††\(P < 0.01\) between groups.](http://jap.physiology.org/content/104/2/365/F1)

---

**J Appl Physiol • VOL 104 • FEBRUARY 2008 • www.jap.org**


**IL/Hep Infusion vs. Saline and AICAR Infusions**

The 150-min IL/hep infusion alone raised plasma FFA by ~60% and glycerol by ~80% (P < 0.05–0.01) (Table 1). This resulted in a small but significant fall in fasting glucose (P ≤ 0.05), with no changes in insulin or glucagon (Table 1). There were also no changes induced by the IL/hep infusion in HGP, Ra, and MCRg, but GFexog fell significantly (P < 0.05) by ~20% (Table 1). The effects of increasing FA supply compared with the AICAR infusion at 150 min were different (Table 1). Plasma glucose did not change; however, in the IL/hep group, the change in plasma lactate was markedly reduced (P < 0.001) and, as expected, FFA and glycerol were raised, compared with the responses observed in the AICAR studies (P ≤ 0.05–0.01) (Table 1). The modest significant increments observed for HGP, Ra, MCRg, and GFexog with AICAR were not observed in the IL/hep studies (Table 1). There was no relationship between the changes in plasma glucagon and HGP with the combined AICAR and IL/hep groups (r = 0.40, P = 0.22). After the IL/hep infusion, there were no changes (Δ) in intramuscular substrates (Δglucose = −0.05 ± 0.27 mmol/l, ΔG6P = 0.7 ± 0.7 mmol/kg dry wt, Δlactate = 0.51 ± 0.50 mmol/l, Δglycogen = 15 ± 33 mmol/kg dry wt, and ΔACCβ-pSer221 = 0.03 ± 0.05 arbitrary units).

**Exercise With or Without IL/Hep Infusion**

The exercise-induced responses of plasma substrates in the presence or absence of excess FA supply were similar for increments observed for HGP, Ra, MCRg, and GFexog with AICAR were not observed in the IL/hep studies (Table 1).

---

**Table 1. Comparison of the absolute and incremental effects of 60-min and 150-min AICAR infusion and 150-min saline or IL/heparin infusion on plasma substrates and hormones, glucose turnover, and skeletal muscle substrates in 6 resting normal dogs**

<table>
<thead>
<tr>
<th></th>
<th>AICAR Infusion</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After 60 min</td>
<td>After 150 min</td>
<td>Δ During 0–150 min</td>
<td></td>
</tr>
<tr>
<td><strong>Glucose, mmol/l</strong></td>
<td>5.0 ± 0.1</td>
<td>4.7 ± 0.3*</td>
<td>5.3 ± 0.4</td>
<td>0.2 ± 0.4</td>
<td></td>
</tr>
<tr>
<td><strong>Insulin, mIU/l</strong></td>
<td>4.4 ± 0.6</td>
<td>5.0 ± 0.6</td>
<td>5.0 ± 0.6</td>
<td>1.4 ± 0.6</td>
<td></td>
</tr>
<tr>
<td><strong>Glucagon, ng/l</strong></td>
<td>53 ± 11</td>
<td>75 ± 10</td>
<td>68 ± 13</td>
<td>16 ± 7</td>
<td></td>
</tr>
<tr>
<td><strong>Lactate, mmol/l</strong></td>
<td>0.6 ± 0.1</td>
<td>1.1 ± 0.1*</td>
<td>1.6 ± 0.1*</td>
<td>1.1 ± 0.1</td>
<td></td>
</tr>
<tr>
<td><strong>FFA, mmol/l</strong></td>
<td>0.68 ± 0.10</td>
<td>0.44 ± 0.08a</td>
<td>0.39 ± 0.08a</td>
<td>−0.29 ± 0.12</td>
<td>−5 ± 10</td>
</tr>
<tr>
<td><strong>Glycerol, mmol/l</strong></td>
<td>97 ± 8</td>
<td>85 ± 8</td>
<td>92 ± 11</td>
<td>−5 ± 10</td>
<td></td>
</tr>
<tr>
<td><strong>HGP, μmol·kg⁻¹·min⁻¹</strong></td>
<td>12.7 ± 0.9</td>
<td>16.0 ± 1.1b</td>
<td>17.1 ± 1.1b</td>
<td>4.4 ± 1.1</td>
<td></td>
</tr>
<tr>
<td><strong>Ra, μmol·kg⁻¹·min⁻¹</strong></td>
<td>12.9 ± 0.8</td>
<td>16.7 ± 1.2a</td>
<td>16.7 ± 1.2a</td>
<td>3.8 ± 0.6</td>
<td></td>
</tr>
<tr>
<td><strong>MCRg, ml·kg⁻¹·min⁻¹</strong></td>
<td>2.5 ± 0.1</td>
<td>3.6 ± 0.4a</td>
<td>3.1 ± 0.3</td>
<td>0.6 ± 0.1</td>
<td></td>
</tr>
<tr>
<td><strong>GFexog, μmol·kg⁻¹·min⁻¹</strong></td>
<td>10.4 ± 0.8</td>
<td>11.9 ± 0.5</td>
<td>11.9 ± 0.5</td>
<td>1.5 ± 0.6</td>
<td></td>
</tr>
</tbody>
</table>

**Exercise With or Without IL/Hep Infusion**

<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After 150 min</th>
<th>Δ During 0–150 min</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucose turnover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HGP</strong></td>
<td>12.4 ± 0.9</td>
<td>11.6 ± 0.9</td>
<td>−0.8 ± 1.1*</td>
<td></td>
</tr>
<tr>
<td><strong>Ra</strong></td>
<td>12.5 ± 0.8</td>
<td>11.5 ± 0.8</td>
<td>−1.0 ± 1.1*</td>
<td></td>
</tr>
<tr>
<td><strong>MCRg</strong></td>
<td>2.5 ± 0.1</td>
<td>2.5 ± 0.2</td>
<td>0.0 ± 0.2*</td>
<td></td>
</tr>
<tr>
<td><strong>GFexog</strong></td>
<td>9.9 ± 1.0</td>
<td>8.0 ± 0.5</td>
<td>−1.9 ± 0.6*</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SE. Δ, incremental change; AICAR, 5-aminimidazole-4-carboxamide-1-β-D-ribofuranoside; IL/hep, combined intralipid-heparin; HGP, hepatic glucose production; Ra, glucose rate of disappearance; MCRg, metabolic clearance rate of glucose; GFexog, glycolytic flux. *P ≤ 0.05, †P < 0.02, ‡P < 0.01, and §P < 0.001 within groups; †P ≤ 0.05, ‡P < 0.01, and §P < 0.001 AICAR vs. IL/hep Δ during 0–150 min.
plasma glucose, glycerol, lactate, insulin, and glucagon. No exercise-induced increments for plasma FA were observed in the IL/hep group, since the FFA levels were already raised preexercise above those seen postexercise for the non-IL/hep group (Fig. 3). On the background of the lipid-induced lower basal GFexo (Table 1), the glucose turnover responses to exercise were similar for the IL/hep and non-IL/hep groups for HGP, Rd, MCRg, and GFexo (Fig. 4). Only small responses in the SkM substrates with exercise performed with and without IL/hep infusion were noted (\( \Delta \text{glucose} = 0.3 \pm 0.1 \) vs. \( 0.0 \pm 0.2 \) mmol/l, \( \Delta \text{G6P} = 0.8 \pm 0.6 \) vs. \( 1.0 \pm 0.3 \) mmol/l, \( \Delta \text{lactate} = 2.6 \pm 1.1 \) vs. \( 0.0 \pm 0.3 \) mmol/l (\( P = 0.07 \)), \( \Delta \text{glycogen} = 30 \pm 37 \) vs. \( -35 \pm 36 \) mmol/kg dry wt (\( P = 0.09 \)), and \( \Delta \text{ACC-}p\text{Ser}^{221} = 0.29 \pm 0.06 \) vs. \( 0.23 \pm 0.15 \) arbitrary units, respectively).

**DISCUSSION**

Three main questions are addressed in these acute in vivo studies: 1) what are the differences between the downstream metabolic responses of moderate 30-min exercise and 60-min AICAR infusion, 2) what is the metabolic impact of a modest elevation of FA (with its accompanying increase in basal SkM FA uptake and oxidation) (45) compared with that of AICAR, and 3) does an increased supply of FA during exercise alter the downstream metabolic response to moderate exercise?
ploying the same animals for all studies, we found that the exercise-induced metabolic responses differed from the responses observed with AICAR. The AICAR and IL/hep infusion metabolic responses also differed, with GF_{exog} rising with AICAR but falling with IL/hep. There was no in vivo metabolic impact on glucose turnover or SkM metabolism with the exercise performed with or without a concurrent IL/hep infusion.

First, considering the exercise- and AICAR-induced metabolic responses, we noticed that plasma FFA and glycerol rose sharply with exercise; however, with acute AICAR, FFA fell. Glycerol levels were unchanged. These latter metabolic responses to AICAR are consistent with inhibition of lipolysis within the adipocyte (12) and SkM (1, 45) and enhanced removal and oxidation of FA (28, 30, 45). As expected, HGP, R_d, and MCR_g all increased with both exercise (8, 10, 39, 49) and AICAR infusion (3, 5, 6, 9, 33), although responses were about threefold greater with exercise. Furthermore, GF_{exog} only increased significantly with exercise (Fig. 2). However, it should be noted that the positive responses of HGP to exercise and AICAR are due to different mechanisms. With exercise, HGP is stimulated by a combination of substrate, hormonal, and neurogenic stimuli (39, 50). On the other hand, the AICAR-induced increase in HGP is due to direct allosteric stimulation by ZMP of hepatic glycogenolysis, as discussed by Comacho et al. (5). The exercise-induced changes in SkM (increased G6P and decreased glycerol concentration) were not observed in the AICAR-treated animals, but ACC_{pSer}^{221} concentrations rose similarly in both groups. These SkM data, combined with the marked increases of HGP, R_d, MCR_g, and particularly GF_{exog} in the exercise studies (vs. AICAR) are consistent with a greatly increased exercise-induced uptake and flux of glucose metabolites down the glycolytic pathway (39, 49). The combined increase of glucose uptake and its metabolic flux and the increased SkM glycogenolysis during exercise led to the observed elevation of SkM G6P. However, it is important to note that the sources of the increased ATP production with exercise and with AICAR are different. With exercise, the increased SkM ATP supply is from oxidation of glucose [derived from plasma glucose and SkM glycogenolysis (39, 49)] and FАОx [derived from peripheral and SkM lipolysis (39, 49)]. In contrast, with AICAR, G_{ox} and FАОx are solely derived from oxidized plasma substrates (28, 30, 32). This is supported by recent observations obtained in isolated electrically stimulated rat soleus muscle, in which the addition of AICAR to the perfusion medium failed to further enhance the contraction-induced SkM endogenous FАОx (46). In fact, the endogenous SkM triacyl glycerol hydrolysis was blunted (46). Thus the known beneficial effects of exercise on triacyl glycerol hydrolysis are unlikely to occur with AICAR infusion alone.

The second issue addressed in our studies was whether the metabolic responses to enhanced intracellular FАОx, induced by either the 150-min AICAR or IL/hep infusions, were similar. We noted that, after both AICAR and IL/hep infusion, glucose turnover (HGP, R_d, MCR_g) were similar, but GF_{exog} was suppressed during the IL/hep infusion (Table 1). These data support the in vitro observations in isolated muscle that AICAR-induced FАОx does not suppress G_{ox} (45), whereas increased FАОx induced by excess FA supply does suppress GF_{exog}, due to the Randle effect (34). SkM ACC_{pSer}^{221} rose only in the AICAR group, whereas intracellular glucose was significantly decreased with AICAR but was unchanged with IL/hep. Together, these data reflect that AICAR increases both G_{ox} and FАОx (45), in contrast to the potential inhibition of intracellular glucose metabolism during IL/hep infusion (31, 34). These data are supported by a recent study that used resting perfused rat soleus muscle strips, exposed to AICAR alone vs. low- and high-FFA concentrations. With AICAR alone, SkM exogenous FАОx increases only 35%, although G_{ox} increases two- to threefold; on the other hand, in response to high FFA concentrations, SkM exogenous FАОx was enhanced two- to threefold and G_{ox} was unchanged (45).

The third issue examined was, given that resting in vivo and in vitro SkM metabolic states induced by IL/hep infusion favor FАОx rather than G_{ox} (31, 4), whether the metabolic responses to moderate acute exercise with or without prior exposure to increased FA supply are altered. Earlier studies of the effect of raised FA supply on acute moderate exercise-induced glucose turnover are confusing, probably reflecting the different species and protocols employed (20, 37, 40, 46). In humans, glucose uptake, both whole body (40) and across leg thigh muscle (20), is either reduced (40) or unchanged (20, 31), whereas glycogen sparing during exercise and IL/hep infusion is generally increased (13, 20, 31, 40). However, these apparent contradictions in data probably reflect different intensities of workloads employed in these studies. When one only includes human studies in which acute (30–60 min) moderate exercise (V_{O2max} of ~50–70%) is employed during the IL/hep infusion, more uniform metabolic responses are observed. Glucose uptake is unaltered, glycogen sparing occurs, G_{ox} is decreased, FA_{ox} is increased, and pyruvate dehydrogenase activity is partially reduced during combined IL/hep infusion and moderate exercise (13, 31).

In the present study, with moderate acute exercise, the exercise-induced responses of glucose turnover (HGP, R_d, MCR_g, and GF_{exog}) were similar in the IL/hep and non-IL/hep exercise studies (Fig. 4), despite the reduced resting GF_{exog} in the IL/hep-infused dogs. SkM lactate oxidation is markedly increased with exercise (25); therefore, the incremental increase of SkM lactate noted in our IL/hep-infused exercising dogs is consistent with a partial inhibition of pyruvate dehydrogenase in exercised SkM with IL/hep infusion (17, 31). However, the exercise-induced rise in SkM lactate in the IL/hep-infused dogs was of insufficient magnitude to be reflected in the measured in vivo GF_{exog} rate during exercise. We also noted some sparing of SkM glycogen during exercise and IL/hep infusion, compared with that shown with exercise alone. Thus the present studies are in general agreement with the earlier studies in humans (13, 20, 31).

Finally, two other issues need clarification. First, in our studies, we compared the metabolic responses of 30-min exercise to 60-min AICAR infusion and 150-min AICAR infusion to 150-min physiological elevation of plasma FFA. To match the acute response to exercise with the acute metabolic response to AICAR infusion, we noted in our earlier AICAR infusion studies (9) that the near-maximal metabolic response to the 150-min AICAR infusion occurred by 60 min (see Table 1). It is also well established that the acute downstream metabolic responses of increased plasma FFA on in vivo glucose transport and oxidation are reached by 150 min (38). Thus the comparisons between exercise and AICAR and IL/
hep and AICAR were reasonably matched in time in the present study. Whether this reflects a true “metabolic” matching cannot be resolved at this time. Second, the present ACCβ-pSer221 data confirm our and other workers’ reports of increased ACCβ-pSer221 in liver (5, 6) and in SkM (9) (consistent with activation of endogenous AMPK activity) utilizing the dose of AICAR used in the present study. Furthermore, the downstream in vivo metabolic responses of glucose turnover observed in the present study with AICAR and exercise closely match those of published studies in dogs (5, 6, 8–10, 33). Therefore, it seems reasonable that the in vivo and SkM metabolic responses observed here are due to direct stimulation by exercise or the AICAR infusion.

In conclusion, the metabolic and SkM responses to moderate acute exercise are unique with respect to in vivo changes in glucose turnover and SkM metabolism and FA metabolism. In particular, endogenous glycogenolysis and lipid hydrolysis are observed only with exercise and not with an acute AICAR infusion, and the stimulation of glucose turnover by exercise is more intense than results shown with AICAR (albeit by different mechanisms). These favorable exercise-induced responses in glucose turnover are not significantly altered by the presence of excessive FA supply, although some limitations of SkM Gox and glycogen sparing are observed. Thus a single dose of AICAR does not mimic the complex metabolic responses observed with acute moderate exercise, nor does a short-term increase in FA supply alter these responses to exercise.

ACKNOWLEDGMENTS

Expert care and surgical assistance of the animals was by Sue McKay and Lilliana Pepe. The excellent assistance of Drs. Zhi-Ping Chen and Bruce Kemp (St. Vincent’s Institute of Medical Research, St. Vincent’s Hospital, Fitzroy, Australia) and Rodney Snow (School of Exercise and Nutritional Sciences, Deakin University, Burwood, Australia) in the performance and interpretation of the SkM AMP and ACCβ and nucleotide assays, respectively, is gratefully acknowledged.

Present address of C. Rantzau: University of Melbourne, Department of Medicine (AHH/NH), Heidelberg Repatriation Hospital, Heidelberg Heights, 3081 Victoria, Australia.

GRANTS

This research was supported by grants to F. P. Alford from the National Health and Medical Research Council of Australia and Diabetes Research Foundation.

REFERENCES


